MARKET

ALIM

ALIM

Alimera Sciences
NASDAQ
3.580
+0.130
+3.77%
Closed 16:00 12/02 EST
OPEN
3.450
PREV CLOSE
3.450
HIGH
3.600
LOW
3.420
VOLUME
10.56K
TURNOVER
19.44K
52 WEEK HIGH
7.92
52 WEEK LOW
3.360
MARKET CAP
25.09M
P/E (TTM)
-1.3561
1D
5D
1M
3M
1Y
5Y
Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administration
Data was included in scientific programming at the annual meeting of The Retina SocietyATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patien...
GlobeNewswire · 5d ago
Alliance Global Partners Downgrades Alimera Sciences to Neutral, Lowers Price Target to $4.5
Benzinga · 11/21 13:29
--Alliance Global Partners Downgrades Alimera Sciences to Neutral Rating From Buy, Adjusts Price Target to $4.50 From $11
--Alliance Global Partners Downgrades Alimera Sciences to Neutral Rating From Buy, Adjusts Price Target to $4.50 From $11
MT Newswires · 11/21 09:40
Alimera Sciences Third Quarter 2022 Earnings: Misses Expectations
Alimera Sciences ( NASDAQ:ALIM ) Third Quarter 2022 Results Key Financial Results Revenue: US$13.6m (up 12% from 3Q...
Simply Wall St. · 11/16 10:05
BRIEF-Alimera Sciences Announces Q3 Financial Results
Reuters · 11/14 17:22
Alimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -102.70% and 12.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/14 13:55
Alimera Sciences Q3 EPS $(0.75) Misses $(0.40) Estimate, Sales $13.60M Miss $15.17M Estimate
Benzinga · 11/14 12:39
Alimera Sciences GAAP EPS of -$0.75 misses by $0.35, revenue of $13.6M misses by $1.45M
Seekingalpha · 11/14 12:32
More
About ALIM
Alimera Sciences, Inc. is a pharmaceutical company. The Company is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. The Company focuses on diseases affecting the retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant that treats patients by delivering a continuous microdose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. The Company’s product ILUVIEN is also used for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Its ILUVIEN is also used in the European Economic Area (EEA) to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The Company commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.

Webull offers kinds of Alimera Sciences Inc stock information, including NASDAQ:ALIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALIM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALIM stock methods without spending real money on the virtual paper trading platform.